Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study.
Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study.
复制标题
DOI：
10.3389/fendo.2021.714447
复制
发表时间：
2021
影响因子：
5.2
通讯作者：
Kaneto H
中科院分区：
文献类型：
--
作者：
Sanada J;Kimura T;Shimoda M;Tomita A;Fushimi Y;Kinoshita T;Obata A;Okauchi S;Hirukawa H;Kohara K;Tatsumi F;Nakanishi S;Mune T;Kaku K;Kaneto H
目前，2型糖尿病(T2 DM)患者经常服用每日DPP-4抑制剂。近年来，一周一次的以胰岛素为基础的注射用度拉鲁肽的研制引起了人们的广泛关注。在这项研究中，我们的目的是研究每周一次的GLP-1受体激活剂(GLP-1RA)对血糖控制以及各种代谢参数的可能影响。在“研究一(前后比较)”中，我们对每日服用DPP-4抑制剂和每周服用一次度那路肽的血糖控制效果进行了直接比较，并在“研究二”中采用倾向评分匹配法设置了对照组。在研究1中，从每日DPP-4抑制剂改为度那路肽显著改善了T2 DM受试者的血糖控制。这种影响在控制不佳的受试者中更为明显。在1：1倾向评分匹配后，在研究2中，转换组与非转换组相比，血糖控制有所改善。我们应该记住，无论年龄、体重和糖尿病病程如何，从每日DPP-4抑制剂转换为每周一次的GLP-1RA度格鲁肽对T2 DM患者的血糖控制具有更有利的效果，特别是当我们无法获得每日DPP-4抑制剂的良好血糖控制时。
At present, daily DPP-4 inhibitors are quite frequently prescribed in subjects with type 2 diabetes mellitus (T2DM). Recently, it has been drawing much attention that once-weekly incretin-based injection dulaglutide was developed. In this study, we aimed to examine the possible effects of once-weekly GLP-1 receptor activator (GLP-1RA) dulaglutide on glycemic control as well as various metabolic parameters. We made a direct comparison between the effect of daily DPP-4 inhibitor and once-weekly dulaglutide on glycemic control in “study 1 (pre–post comparison)” and set the control group using the propensity score matching method in “study 2”. In study 1, switching from daily DPP-4 inhibitor to dulaglutide significantly ameliorated glycemic control in subjects with T2DM. Such effects were more obvious in poorly controlled subjects. After 1:1 propensity score matching, the switching group improved glycemic control compared with the non-switching group in study 2. We should bear in mind that switching from daily DPP-4 inhibitor to once-weekly GLP-1RA dulaglutide exerts more favorable effects on glycemic control regardless of age, body weight, and duration of diabetes in subjects with T2DM, especially when we fail to obtain good glycemic control with daily DPP-4 inhibitor.
登录
查看更多内容
DOI：
10.1056/nejmoa1603827
发表时间：
2016-07-28
期刊：
The New England journal of medicine
影响因子：
--
作者：
Marso SP;Daniels GH;Brown-Frandsen K;Kristensen P;Mann JF;Nauck MA;Nissen SE;Pocock S;Poulter NR;Ravn LS;Steinberg WM;Stockner M;Zinman B;Bergenstal RM;Buse JB;LEADER Steering Committee;LEADER Trial Investigators
通讯作者：
LEADER Trial Investigators
影响因子：
168.9
作者：
Turner, RC;Holman, RR;Ward, JD
通讯作者：
Ward, JD
影响因子：
158.5
作者：
Gaede, Peter;Lund-Andersen, Henrik;Pedersen, Oluf
通讯作者：
Pedersen, Oluf
影响因子：
8.2
作者：
Davies, Melanie J.;D'Alessio, David A.;Buse, John B.
通讯作者：
Buse, John B.
DOI：
10.1111/dom.12005
发表时间：
2013-02
期刊：
Diabetes, obesity & metabolism
影响因子：
--
作者：
Hamamoto S;Kanda Y;Shimoda M;Tatsumi F;Kohara K;Tawaramoto K;Hashiramoto M;Kaku K
通讯作者：
Kaku K